Gastrointestinal Stromal Tumors
True or false: Prolonged adjuvant imatinib therapy extends overall survival in patients with high-risk GIST.
Results of a phase 1 trial indicate ripretinib may be a beneficial treatment option for patients with refractory advanced GIST.
Prolonged adjuvant imatinib for high-risk GIST led to a superior OS over shorter-term imatinib treatment, according to a trial comparing 3- and 1-year regimens.
Which of the following combination treatment options has yielded the best outcomes in patients with stage IV GIST?
Using first-line multi-kinase inhibitors (MKIs) aside from imatinib did not lead to early resistance or decreased efficacy of second-line therapy for metastatic GIST.
A retrospective analysis suggests that the clinical features and treatment approaches for multiple GISTs may differ from single GISTs, presenting a gap in the treatment landscape.
Axitinib in combination with octreotide acetate showed activity and tolerable safety in patients with G1-G2 NETS of non-pancreatic origin.
Lanreotide combined with pembrolizumab led to stable disease with acceptable safety in nearly 40% of patients with gastroenteropancreatic neuroendocrine tumors (GEPNETs), according to results…